Zacks Investment Research on MSN11d
AXSM Stock Down Despite ADHD Study Meeting Primary EndpointAxsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback